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ABSTRACT 
 
REGULATION OF CERVICAL EPITHELIAL CELL PROLIFERATION BY VASCULAR 
ENDOTHELIAL GROWTH FACTOR. (May 2012) 
 
Siobhan Maureen Donnelly, B.A., University of Great Falls 
 
M.S., Appalachian State University  
 
Chairperson:  Chishimba Nathan Mowa 
 
Cervical remodeling is a complex biological process, characterized in part by vascular 
leakage, an increase in edema, and epithelial growth.  Here, we examined the effects of 
vascular endothelial growth factor (VEGF) primarily on cervical epithelial growth.  Both 
timed-pregnant and non-pregnant mice were treated with either recombinant VEGF164 
protein, vehicle only or VEGF blocker.  The tissues were analyzed using a variety of 
techniques, including scanning electron microscopy, confocal immunofluorescence, BrdU, 
and quantitative real-time PCR.  From these studies, we show that VEGF induces cervical 
epithelial cell, edema, and inter-epithelial immune cell migration into cervical lumen, 
possibly by altering expression of a tight junction molecule (claudin-5) and expression of 
itself (VEGF) and its receptors (KDR and Flt-1).  These results demonstrate that VEGF is an 
important regulator in cervical remodeling, notably by altering various events in the cervical 
epithelial cells.  
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INTRODUCTION 
 
 
One of the most important health problems in obstetrics currently is pre-term birth 
and its associated complications (Garfield, Maner, Shi, Shi & Saade, 2006).  In humans, pre-
term delivery is defined as birth prior to 37 weeks.  Pre-term labor poses a significant 
challenge to health in that 5-25% of all deliveries are pre-term and up to 75% of all perinatal 
mortality (Mokuolu, Suleiman, Adesiyun & Adeniyi, 2010).  Further, it (pre-term) is the 
second leading cause of infant mortality accounting for 16% of all infant deaths and is 
associated with significant morbidity (Fogleman et al., 2007).  The underlying causes of 
premature birth have been and are still being studied extensively. However, there is no 
effective cure and the exact trigger of this anomaly is still not completely understood. This 
study aims to examine the effects of vascular endothelial growth factor (VEGF) on the 
proliferation of cervical epithelial cells.  Cervical epithelial cell proliferation accounts for 
50% of cervical tissue growth during pregnancy and is also believed to play a role in cervical 
tissue immune response (Burger & Sherwood, 1998). 
 
Premature Birth 
 Pre-term birth can be caused by a number of factors, including infection, obesity, 
multiple births, assisted reproductive techniques, obstetric interventions, diet, genetics and 
(Hudic et al., 2009) endocrinologic factors, such as increasing androgen concentration, 
hyperprolactinameia, and defects in luteal phase (Furui, Imai & Ohno, 2007).  Further, an 
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increasing number of women now have children in their mid-age and tend to delay marriage 
and child-bearing until later in life, when they have finished their education or when their 
professional careers are well-established (Tabcharoen, Pinjaroen, Suwanrath & Krisanapan, 
2009).  This trend may also account for the recent increase in pre-term labor rates 
(Tabcharoen et al., 2009).  Of all these etiologies listed above, infection is one of the leading 
causes of pre-term birth, accounting for about 50% preterm and induces inflammation and 
vascular changes in the birth canal or cervix (Bosquiazzo et al., 2005).   
 
Basic Anatomy of the Female Reproductive System 
  The basic structures of the female reproductive system include the a) ovaries, the 
source and site of egg maturity; b) fallopian tubes, site of fertilization and initial 
development of the embryo; and c) uterus, “house” for the fetus until birth.  The most 
external reproductive tissue of the female reproductive system is the vagina.  Between the 
vagina and the uterus is the cervix. My project focuses on the cervix. 
 The cervix is cylindrically-shaped and is located on the caudal part of the uterus and 
protrudes and opens through the upper anterior vaginal wall into the vagina.  The surface of 
the ectocervix, the portion of the cervix extending in the vagina, is covered with squamous 
epithelium, while the endocervix is the portion that extends on the opposite end, into the 
uterus (Bauer et al., 2007). The endocervix forms the mucous membrane, with its glands and 
folds covered with columnar epithelium (Bauer et al., 2007).  The cervix is composed mainly 
of fibrous connective tissue, with the main component being collagen.  It is also composed of 
smooth muscle.  The collagen is responsible for its rigidity and mechanical function (Bauer 
et al., 2007) and makes up the extracellular matrix (Garfield et al., 2006).   
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The Cervix and its Role during Pregnancy    
 One of the roles of the cervix during pregnancy and term is to provide mechanical 
resistance to the ever increasing gravitational force exerted by the growing fetus, and thus, 
ensure the normal development of the fetus (Garfield et al., 2006).  This task by the cervix is 
possible because of its composition, i.e., its extracellular matrix, which enables it to function 
as a fiber-reinforced composite.   
 The cervix also serves as a mechanical and biochemical barrier that separates the 
vaginal bacterial flora from the sterile uterine-located fetal amniotic cavity.  The changes that 
the cervix undergoes during and immediately after pregnancy are collectively termed cervical 
remodeling (CR) (Bauer et al., 2007).  This complex process is regulated by various factors, 
which ultimately lead to catabolic processes such as degradation of collagen. However, the 
exact underlying mechanisms are not completely understood (Bauer et al., 2007). Here, we 
examine the role of VEGF in this process, particularly its role in cervical epithelial cellular 
growth.  
 
Cervical Remodeling 
CR is a progressive complex biological process that can be separated into four 
distinct but overlapping phases, namely softening, ripening, dilation and effacement, and 
post-partum repair (Challis, 2000).  CR, ultimately, if accompanied by adequate uterine 
contraction, will lead to fetal passage.  Failure of either or both of these events leads to 
birthing problems, such as preterm birth and protracted labor, which account for 75% of fetal 
mortality (Challis, 2000).  
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Studies in humans have shown that cervical softening starts as early as the first 
trimester, whereas in mice, softening usually begins by day 12 of the 19-day gestation period 
(Timmons & Mahendroo, 2007).  During softening, there is a measurable decline in cervical 
tissue compliance or tensile strength (Leppert, 1995; Read, Word, Ruscheinsky, Timmons & 
Mahendroo, 2007; Timmons, Akins & Mahendroo, 2010).  The second phase of CR, the 
ripening phase, is an accelerated phase during which there is a great loss of tissue compliance 
and integrity.  This is the shortest of the four phases and occurs in the hours prior to birth in 
mice and up to a few weeks before birth in humans (Leppert, 1995; Read et al., 2007).  The 
third phase of CR follows ripening and occurs as the cervix relaxes, dilates, and effaces and 
is initiated when the uterine contractions become more frequent.  This ultimately leads to 
labor and the final passage of the fetus (Kelly, 2002).  Immediately following birth, post-
partum repair begins and the cervical tissue begins the restoration process to its non-
pregnant, non-compliant state (Leppert, 1995).  Dysfunction in any of the phases can lead to 
serious obstetrical complications.  Some of the complications can include preterm birth and 
protracted labor (Leppert, 1995).    
Although significant strides have been made in understanding mechanisms that 
underlie CR, the exact factors that regulate CR, and specifically events such as increase in 
cervical tissue and fluid content, are not fully understood.  Other prominent features of CR, 
other than increase in tissue size and edema include vascular alteration such as increased 
permeability, angiogenesis and vasodilation (Collins, Wilson, Fischer-Colbrie & Papka, 
2000; Mowa et al., 2004a). In particular, very little is known about the role of local 
microvascular alterations, the factors that regulate them and the relationships, if any, between 
5 
 
tissue edema and local cervical vascular changes. This project examines the relationship 
between vascular factors and changes in cervical size.  
 
Cervical Size during Pregnancy 
Increase in cervical tissue mass during pregnancy is believed to be influenced by 
factors such as relaxin, prostaglandin, and sex hormones (Burger & Sherwood, 1995).  Based 
on scanning electron microscopy (SEM) data we have hypothesized that VEGF may play a 
role in this process, specifically by promoting cervical epithelial cellular growth, possibly by 
either directly stimulating endothelial cells to secrete growth factors that, in turn, stimulate 
proliferation of local cervical epithelial cells (Mowa et al., 2004a; Mowa & Papka, 2004b, 
Mowa et al., 2008).  Secondly, VEGF may also induce vascular permeability leading to an 
increase in infiltration of local tissue and induction of epithelial growth by serum factors, 
which are a rich source of growth factors (Tomanek & Schatteman, 2000).  Both of these 
mechanisms could be operational in the cervix, and in part, account for the phenomenal 
epithelial proliferation during cervical ripening, perhaps in collaboration with factors such as 
sex steroid hormones, prostaglandins, and relaxin.  In our previous study, we used SEM to 
show pronounced effects of VEGF on cervical epithelial folds in ovariectomized rats treated 
with VEGF in comparison to the control group (Mowa et al., 2008). The present study builds 
on this earlier data and uses a more definitive test for evaluating VEGF-induced growth of 
epithelial cells, namely bromodeoxyuridine (BrdU).   
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Role of Cervical Epithelia 
 The functions of cervical epithelium during pregnancy are very specific for each stage 
of the pregnancy (Read et al., 2007).  The major role of epithelia during the softening stage 
of pregnancy is in protection through increased expression of surveillance factors.  Towards 
the end of pregnancy, the cervical epithelium expresses proteins that promote ripening and 
alter barrier properties of the cervix (Read et al., 2007).  There is growing research interest 
aimed at understanding the roles and underlying mechanisms of the epithelia in CR (Garfield 
et al., 2006).   
 
Vascular Endothelial Growth Factor 
 Vascular events in the remodeling cervix are prominent during and immediately after 
pregnancy.  VEGF is the best studied vascular regulator and is known to be the key regulator 
of angiogenesis, which occurs during different physiological processes, such as 
embryogenesis, skeletal growth, and reproductive functions (Ferrara, Gerber & LeCouter, 
2003).   Angiogenesis is associated with endothelial cell proliferation, migration, and 
diminished apoptosis (Ferrara et al., 2003; Neufeld, Cohen, Gengrinovitch & Poltorak, 
1999). 
VEGF is a chemokine produced by cells such as fibroblasts and a member of a family 
of closely related growth factors that include VEGF-A, -B, -C, -D, -E, and placenta growth 
factor (PIGF) (Ferrara & Davis-Smyth, 1997).  VEGF-A has well-established biological 
effects and exists as several splice variants (Ferrara & Davis-Smyth, 1997).  The five 
different isoforms of VEGF are synthesized from alternative splicing from a single VEGF 
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gene.  These isoforms contain 8 exons and are located at human chromosome 6p12-p21 
(Ferrara & Davis-Smyth, 1997).   
The different species of mRNA that encode for the VEGF protein have been 
identified and are found to be expressed in a tissue-specific manner (Ferrara & Davis-Smyth, 
1997).  These specific mRNA species increase from differential splicing, with the 165 amino 
acid form of VEGF lacking sequences encoded by exon 6, and the 121 amino acid form 
lacking exon 6 and 7 sequences (Ferrara & Davis-Smyth, 1997).  The different VEGF 
isoforms differ in their molecular mass and biological properties.  It is important to note here 
that there are three isoforms of VEGF-A that are known to be expressed in the cervix of 
rodents (164, 199, 205), the most predominant one being VEGF164 (Mowa et al., 2004a, b). 
 
VEGF Receptors 
 Biological effects of VEGF are largely mediated by two receptors: VEGFR-1 (Flt-1) 
and VEGFR-2 (KDR/Flk-1), which have significantly different signaling properties and are 
almost exclusively expressed by endothelial cells (Ferrara et al., 2003).  VEGF receptor 1 
(VEGFR1 or Flt-1) is the high affinity receptor for VEGF and is the gene product of Flt-1, 
FMS-like tyrosine kinase.  Kinase insert domain receptor, KDR, codes for VEGF receptor 2, 
VEGFR2, which is also known as Flk-1 (Ferrara & Davis-Smyth, 1997).  Other cellular 
targets of VEGF that express VEGF receptors include osteoblasts, mononuclear phagocytes, 
hematopoietic cells, and some malignant cells (Chen, Ye & Xie, 2004).  Our lab has localized 
the two primary VEGF receptors, KDR and Flt-1, in the endothelial, epithelial, and stromal 
cells in cervical tissues (Mowa et al., 2004a).    
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Purpose of Study 
 CR is a vital part of the birth process and maybe regulated by multiple cervical cell 
types.  Recent data indicates that the cervical epithelial cells may be the key cell type that 
plays a primary role in regulating CR.  The purpose of the present study is to determine if 
VEGF has a functional role in regulating cervical epithelial processes, such as proliferation.   
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MATERIALS AND METHODS 
Animals and Treatments 
Female C57BL6/129SvEv mice sourced from Charles Rivers were used in these 
studies (n=3) under different treatments (VEGF agents, i.e., recombinant protein or 
inhibitor), as described in further details below or physiological conditions (pregnant or 
ovariectomized non-pregnant). Prior to tissue harvest, animals were administered a lethal 
injection of Sodium Pentobarbital (Sleepaway
®
, Fort Dodge Laboratories Inc., Burlingame, 
CA) and perfused intra-cardially immediately thereafter with 0.9% normal saline.  Cervical 
tissues were carefully harvested under a stereomicroscope to ensure only cervical tissue was 
harvested.  The tissues were then processed and analyzed appropriately. Animals used were 
either pregnant or non-pregnant, as described in more details below.  All experiments were 
performed in accordance
 
with the Guide for the Care and Use of Laboratory Animals of
 
the 
local institution (Appalachian State University) and the NIH guidelines (NIH publication
 
number 86-23), and efforts were made to minimize both animal
 
suffering and numbers of 
animals used.  Following treatments, tissues were analyzed using various techniques, 
including morphological techniques [basic immunohistochemistry (BrdU), SEM, 
immunofluorescence] and gene expression (Real time PCR) in order to elucidate the effects 
of VEGF on various cervical parameters and events, namely cervical epithelial structure and 
proliferation. 
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Surgery:  Ovariectomization 
 Before treatments or harvesting of tissues in the non-pregnant mice, the mice are 
ovariectomized (ovariectomy = removal of ovaries).  Prior to ovariectomy, animals were 
anaesthetized with ketamine and xylazine (43-129 mg ketamine and 8.6-26 mg xylazine per 
gram of body weight) and then allowed to rest for seven days post-surgery before performing 
the experiments, to allow complete removal of residual ovarian sex steroid hormones in 
plasma.  
 
Treatments 
 Appropriate treatments with either vehicle only [negative control: 0.1 M PBS mixed 
with saturated (25%) pluronic gel mixed and kept in liquid form under ice] or VEGF agents 
[mouse recombinant VEGF 164 protein (Calbiochem, La Jolla, CA) or mouse recombinant 
VEGF Blocker].  Experiments were undertaken in this manner due to the fact that VEGF 
treatments (dose, route, frequency) had not been optimized in the cervix.      
 
a) Dose-Dependent VEGF Study:  Non-pregnant, ovariectomized mice were divided into two 
groups (n=1) and treated with 50µl of either: 1) mouse recombinant VEGF 164 protein 
(50ng/mouse, 200ng/mouse, or 400ng/mouse), or 2) vehicle (0.1M PBS). Both groups were 
injected in the intra-periotneal cavity (IP) in the morning and intra-vaginally (IV) in the 
evening over a period of four days.  Following treatment, cervical tissues were harvested, 
split into ecto-cervices (end near vagina) and endo-cervices (end near uterus), and fixed in 
2.5% glutaraldehyde (dissolved in 0.1M PBS) immediately after sampling to be analyzed 
using SEM (morphology). 
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b) Time-Dependent VEGF Study:  Non-pregnant, ovariectomized mice were treated with a 
single injection (IP) of recombinant VEGF (200ng/mouse, IP) and divided into 3 different 
groups, based on the time that lapsed after VEGF treatment, i.e., 1hr 45min,  
2hr 45min, and 4hr 45min.  Animals were sacrificed on the second day, as described earlier, 
and tissues were then harvested, and fixed in 10% formalin and were analyzed using 
immunofluorescence (confocal microscopy). 
   
c) Cell Proliferation Study:  Ovariectomized mice were treated with a single injection (IP) of 
recombinant VEGF (400ng/mouse, IP) and divided into 3 different groups, based on the time 
that lapsed after VEGF treatment, i.e., 1hr 45min, 2hr 45min, and 4hr 45min. In addition, a 
day prior to and during VEGF treatment, both groups were also treated with 50µL (IP) BrdU, 
as described by the manufacturer (Invitrogen, Fredrick, MD). Animals were sacrificed on the 
second day, as described earlier, and tissues were then harvested, fixed in 10% formalin, and 
examined using immunohistochemistry (Inverted Olympus Light Microscope). 
 
d) Optimal VEGF Treatment Study:  Ovariectomized mice were divided into 2 treatment 
groups (n=3) as follows: 1) Group 1 was given two consecutive injections of recombinant 
VEGF [200ng dissolved in 25μL of saturated pluronic gel and 0.1M PBS, 25μl/per injection, 
IV] administered at time = 0hr and 4hr.  Animals were sacrificed at 8 hours post-initial 
injection, as described earlier, and tissues were then harvested and frozen at  
-80°C, and examined using quantitative real-time polymerase chain reaction (qRT-PCR). 
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e) Pregnant Baseline Gene Expression Study:  Pregnant animals from days 11-17 of 
pregnancy (n=3) were used (untreated).  Animals were sacrificed on every day of pregnancy 
prior to 12noon, tissues were then harvested and frozen at -80°C, and examined using qRT-
PCR. 
 
f) Pregnant VEGF, VEGF Blocker Gene Expression Study:  Pregnant animals from days 11 
and 17 of pregnancy were divided into three groups and treated with either VEGF (n=3), 
VEGF Blocker (n=3), or vehicle (n=3).  1) Group 1 was given two consecutive injections of 
recombinant VEGF [200ng dissolved in 25μL of saturated pluronic gel and 0.1M PBS, 
25μl/per injection, IV].  2)  Group 2 was given two consecutive injections of VEGF Blocker 
[5mg VEGF Blocker/kg body weight, 50μL/per injection, IP].  3) Group 3 was given two 
consecutive injections of vehicle [25μL of saturated pluronic gel and 0.1 PBS, 25μl/per 
injection, IV].  All treatments were administered at time = 0hr and 4hr and tissues harvested 
at t = 8hr. 
 
Techniques Used in the Study 
I. Determination of VEGF’s Effects on Cervical Epithelial Morphology Using SEM 
 Experiments were undertaken to visualize, in more depth, the effects of VEGF on the 
morphology of cervical epithelia in ovariectomized mice. After overnight fixation in 2.5% 
glutaraldehyde, the tissues were washed with the buffer, then dehydrated in a graded series of 
ethanol, and dried with a critical point drying apparatus (Polaron Instruments Inc., 
Doylestown, PA). All dried samples were mounted on aluminum stubs, sputter coated with 
gold, and imaged with a Quanta 200 SEM (FEI Company, Hilsboro, OR) at 20 kV.  
13 
 
II. Determination of VEGF’s effects on expression of claudin-5 in cervical epithelial cells 
Because our SEM data in VEGF-treated mice showed infiltration of WBC into the 
lumen of the cervix, we sought to examine the effects of VEGF on the expression of a key 
protein known to “glue” epithelial cells together, namely claudin-5, using confocal 
immunofluorescence.  Cryostat sections were cut and processed for confocal immunostaining 
using Claudin-5 (primary dilution: 0.5μg/mL solution; secondary antibody (FITC) dilution: 
1.0μg/mL solution, as described by the manufacturer, Santa Cruz Biotechnology).  Following 
staining, sections were mounted using mounting medium and viewed using a confocal 
microscope (Zeiss LSM510, Thornwood, NY). 
 
III. Determination of VEGF’s effects on cervical epithelial proliferation using BrdU 
This experiment was undertaken to test whether our earlier speculation that VEGF 
causes cervical epithelial cell proliferation, based on increased folds, as revealed by SEM 
data (Mowa et al., 2008), was valid. We utilized BrdU, the gold standard for marking cell 
proliferation. In order to determine the optimal time for VEGF’s effects on cervical epithelial 
cell proliferation, mice were treated with VEGF and BrdU.  Tissues were sectioned using a 
cryostat and processed for immunohistochemistry using anti-BrdU, as described by the 
manufacturer (Invitrogen, Fredrick, MD).  Following staining, sections were counter-stained 
with hematoxylin, dehydrated in a series of ethanol and dipped in xylene before mounting.  
Mounted sections were then viewed and analyzed under a microscope (Inverted Olympus 
Light Microscope). 
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IV. Determination of VEGF, Flt-1, and KDR Gene Expression in the Cervix Studies 
Gene expression analysis was performed using qRT-PCR to determine the extent to 
which different VEGF agents (recombinant VEGF164 protein and VEGF Blocker) influence 
mRNA expression of VEGF and its receptors, KDR and Flt-1, in the cervix of both pregnant 
and non-pregnant mice.  Gene expression analysis was performed in three steps, as described 
below:   
i) Tissue processing, messenger RNA isolation, and quantification:  Following 
treatments, animals were euthanized and trans-cardially perfused with normal saline (0.9% 
sodium chloride).  The cervices were harvested immediately, snap-frozen and either 
processed or stored at -80C until processing. Total RNA was isolated from individual 
cervices using the RNeasy Mini Kit (Qiagen, Valencia, CA) and then the quality and quantity 
of each sample was estimated using Nanodrop Spectrophotometer (ND-1000 V3.1.2, 2001; 
Nanodrop Products,Wilmington, DE).  Aliquots of total RNA were diluted in RNase-free 
deionized (DI) water and either stored at -80C or processed for reverse transcriptase PCR, as 
described below.  
ii) Reverse transcriptase PCR (RT-PCR): Total RNA from the cervical tissue was 
reverse-transcribed and amplified in an Eppendorf Master Cycler (Hamburg, Germany) using 
reagents from Applied Biosystems (Foster, CA). For generation of complementary DNA 
(cDNA), 1.0 µg of previously isolated total RNA was placed in a total volume of 9.5 µL per 
sample with RNase-free water, as was determined by Nanodrop Spectrophotometer, as 
described above. The RNA was incubated for 5 minutes at 65°C and cooled to room 
temperature for 10 minutes. During the cooling period, 9.5 µL of a reverse transcriptase 
master mix was added to each tube, which was comprised of the following:  reverse 
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transcriptase buffer (2 µL per tube of RNA; Applied Biosystems, Foster, CA); MgCl2 (2 µL 
per tube of RNA), dNTP (2 µL per tube of RNA); RNase inhibitor (0.5 µL per tube of RNA); 
RNAse-free water (2µL per tube of RNA); and random hexamers (1 µL per tube of RNA). 
Lastly, 1.0 µL of MuLV reverse transcriptase was added to each tube. One tube received no 
reverse transcriptase enzyme to serve as a non-template control for DNA contamination. The 
Thermocycler was programmed to run at 25°C for 10 minutes, 42°C for 2 hours, 95°C for 5 
minutes, and stored at 4°C. The generated total cDNA was then used to evaluate mRNA 
levels of the genes of interest, as described below.  
iii) Real-time PCR (qRT-PCR):  Relative expressions of the genes of interest (VEGF, 
KDR, and Flt-1) were evaluated using qRT-PCR. Only fold changes equal to or greater than 
2 were accepted as significant. TaqMan
®
 Gene Expression Assays (Applied Biosystems, 
Foster, CA), which are pre-designed and pre-optimized gene-specific probe sets, were 
utilized and DNA amplification was performed using the Applied Biosystems qRT-PCR 
machine (ABI 7300 HT) with the GeneAmp 7300 HT sequence detection system software 
(Perkin-Elmer Corp.) The PCR reactions were set up in wells of 96-well plates in a volume 
of 25 L per well. The reaction components included: 1000 ng (5.0 L) of synthesized 
cDNA, 12.5 L of 2X Taqman
®
 Universal PCR Master Mix, 1.25 L of 20X Assays-on-
Demand
TM
 Gene Mix (e.g. VEGF), and 6.25 L of qRT-PCR-grade RNAse-free water. The 
program was set as follows: an initial step of 50C for 2 min and 95C for 10 min and then 
40 cycles of 95C for 15 s and 60C for 60 s. The relative amount was calculated from the 
threshold cycles with the instrument’s software (SDS 2.0) according to the manufacturer’s 
instructions. Relative expression levels of the target genes were normalized to the geometric 
mean of the endogenous control gene, GUS.
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RESULTS 
VEGF alters structure of cervical epithelial cells and induces WBC migration 
SEM data analyzed from the ecto- and endo- cervices revealed specific VEGF-
induced structural changes in the cervical epithelial cells compared to the control group 
(Figs.1-2).  Specifically, in ecto-cervices, epithelial cells from VEGF-treated animals had 
more folds, appeared edematous, with less pronounced cellular borders (Fig. 1B, D, F), 
compared to the control group (Fig. A, C, E). The most obvious features in endo-cervices of 
mice treated with VEGF compared to the control group were dose-dependent migration of 
WBC into the cervical lumen cells, but also exhibited less prominent borders (Fig. 2B, D, F).  
When treated with 400ng of recombinant VEGF protein/mouse, there was induction of white 
blood cell (WBC) migration in the apical surface of the cervical lumen of endo-cervices and 
layers of the cervical epithelial cells peeled off in both ecto- and endo-cervices (data not 
shown). 
 
VEGF alters gene expression of claudin-5, a cervical inter-epithelial adhesion molecule  
SEM data revealed that VEGF treatment increases the cervical inter-epithelial cellular 
gaps. We sought, therefore, to understand the likely mechanisms underlying this 
phenomenon by examining alteration in the expression of an inter-epithelial adhesion 
molecule, claudin-5. Consistent with our SEM data, the intensity of the immunofluorescence 
of claudin-5 was found to be weak in the cervical epithelial of VEGF-treated mice compared 
to control, based on our subjective assessment (Fig. 3A) i.e., at 1hr 45min, claudin-5
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expression was more intense and was confined to the inter-epithelial cellular space (data not 
shown); whereas, by 4hr 45min, the expression was more diffuse (Fig. 3B), and by 6hr, the 
localization pattern reverted to that seen earlier at 1hr 45min, i.e., it got confined to the inter-
epithelial cellular space. 
 
VEGF induces proliferation of cervical epithelial cells 
Treatment of ovariectomized mice with VEGF induced pronounced proliferation of 
cervical epithelial cells in a time-dependent manner, with the peak expression observed at 4hr 
45min (Fig. 4B, E) and the least amount of expression observed at both 1hr and 6hr, 
respectively (Fig. 4A, C, D, E). Intestines from either group (VEGF or vehicle only treated 
groups) were used as positive control (Fig. 4G).  
 
VEGF alters gene expression of VEGF and its Receptors 
To understand or elucidate the underlying mechanism of VEGF’s effects reported 
above, we sought to examine the effects of VEGF protein on its self and receptors using gene 
expression.  Data generated from real-time PCR analysis showed VEGF down-regulated 
expression of Flt-1 (Fig. 5A), KDR (Fig. 5B), and itself (Fig. 5C) compared to control (n=3).  
These results revealed that VEGF is having an effect on the cervical epithelium based on the 
fact that animals treated with VEGF have a lower expression of the receptors for VEGF and 
VEGF itself (Fig. 5).  
 
VEGF alters gene expression of VEGF and its Receptors in cervices of pregnant mice 
Levels of VEGF mRNA and the mRNAs of both of its receptors were found to 
remain constant from gestational age days 11 through 16, but increased sharply by day 17 of 
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gestational age (p<0.05) (Fig. 6).  In VEGF-treated animals compared to control (n=3), at 
day 11 and 17 of pregnancy; VEGF, KDR, and Flt-1 are being up-regulated.  In VEGF-
blocker treated animals compared to control (n=3), at day 11 and 17 of pregnancy; VEGF, 
KDR, and Flt-1 are being down-regulated (Fig. 7). 
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DISCUSSION 
We have previously shown, using SEM, that exogenous VEGF administered to 
ovariectomized mice induces folding of the cervical epithelia layer, and based on these 
findings, suggested that VEGF induces proliferation of cervical epithelial cells. The present 
study builds on these earlier observations and was aimed at investigating the effect of VEGF 
on cervical epithelial cell proliferation using a more definitive technique, namely, BrdU.  The 
key findings of this study are:  VEGF 1) induced pronounced proliferation of cervical 
epithelial cells in a temporal- and dose-dependent manner; 2) promotes WBC migration into 
the cervical lumen, by diminishing the expression of cervical inter-epithelial cell adhesion 
proteins, such as claudin-5; 3) induces folding and edema in cervical epithelial cells; and 4) 
VEGF Blocker alter mRNA expression of VEGF and its receptors (Flt-1 and KDR), in a 
physiologically-dependent manner.  Collectively, these findings suggest that VEGF plays a 
possible role in CR by influencing the overall growth of the cervix, specifically, events in the 
cervical epithelial cells, which (epithelial cells) are now thought to play the central role in 
cervical remodeling.   
 The induction of edema in cervical epithelial cells by VEGF shown in this study is 
consistent with previous studies that have reported that cervical edema is a prominent feature 
of CR in experimental animals and humans (Burger & Sherwood, 1998; Myers, Socrate, 
Tzeranis & House, 2009).  However, these earlier studies did not identify the factors that 
induce this condition. Here, we show that VEGF is a likely candidate for inducing this 
condition (edema) in the cervix. This conclusion is not unusual in that VEGF’s ability to 
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induce edema in tissues is a well-established phenomenon, especially in tissue types such as 
uterine tissue (Van Bruggen et al., 1999).  In fact, VEGF was first described as a potent 
vascular permeability factor (Senger et al., 1983). For instance, when compared to one of the 
most potent endogenous vascular permeability factors, namely histamine, which is released 
during a bee sting, VEGF is capable of inducing edema about 50,000 times more than 
histamine (Van Bruggen et al., 1999). It is, therefore, likely that VEGF may account for the 
cervical edema that is prominently present in the cervix of humans and experimental animals 
during pregnancy. Future studies in our lab will attempt to address this knowledge gap.   
In edematous tissues, infiltration of WBCs is not uncommon.  However, migration or 
presence of immune cells into the cervical lumen as observed in the present study is an 
interesting phenomenon that has not been reported before, and its functional significance in 
CR, for now, is unclear. It is also not clear at this point whether this observation is 
physiological, i.e., whether it occurs during pregnancy. If indeed it does, it could perhaps 
signify the formation or presence of the first line of defense during pregnancy.  More 
specifically, these cervical luminal migrant immune cells may prevent or inhibit the possible 
entry of vaginal microbes into the uterus.  If vaginal microbes break through the epithelial 
barrier and into the uterus, the consequences would be contamination of the sterile fetal 
amniotic fluid, ultimately leading to placental infection, which is one of the most potent and 
major inducers of preterm birth (Bosquiazzo et al., 2005).  Thus, these immune cells may 
create a buffer zone between the sterile fetal amniotic fluid housed in the uterus and the 
microbe-rich vaginal environment.  This line of defense may complement the well-known 
mechanical barrier to infection provided by epithelial cells which are generally observed at 
the body’s entry points, which, in this particular case, are cervical epithelial cells. To date the 
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types of immune cells infiltrating the cervical lumen remains unknown. However, our 
preliminary data in other projects have demonstrated the presence of macrophages in the 
cervical epithelial during pregnancy and postpartum using the macrophage marker primary 
antibody from Santa Cruz Biotechnolgy (unpublished data). Taken together, if indeed our 
current interpretation is true, VEGF may play an important role in preventing infection-
induced CR and preterm labor in general. 
The exact process mediating VEGF-induced infiltration of immune cells through the 
tightly-regulated cervical inter-epithelial cell border, as revealed by SEM data, is currently 
unclear. However, this phenomenon is not unusual in vascular endothelial cells (Antonetti, 
Barber, Hollinger, Wolpert & Gardner, 1999; Timmons & Mahendroo, 2007). VEGF readily 
induces infiltration of local tissues by microvascular-derived immune cells by vaso-
permeability through alterations in the expression of cell adhesion molecules (Antonetti et 
al., 1999; Timmons & Mahendroo, 2007). Indeed, we have previously shown that VEGF 
alters expression of vascular cell adhesion molecule (VCAM-1) in the cervix of non-pregnant 
and pregnant rodents using DNA microarray studies and real time PCR analysis (Mowa et 
al., 2004a).  However, the present study is the first to demonstrate VEGF’s ability to increase 
intercellular gaps between cervical epithelial cells, which, like all epithelial cells, belong to 
the same general family as vascular endothelial cells. It is feasible that VEGF altered the 
expression of cervical inter-epithelial tight junction (TJ) proteins, such as claudin-5 shown in 
this study.    
Tight junctions have two main components or group of molecules, namely occludin 
and claudin.  More specifically, claudin is a member of a family of proteins consisting of 
over 20 members (Gonzalez-Mariscal, Betanzos, Nava & Jaramillo, 2003).  It has been 
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shown that over-expression of mutant forms of occludin in epithelial cells leads to changes in 
the “gate” functions of the TJ (McCarthy et al., 1996).  Of relevance to the present study, 
claudins are also regulated in cervical epithelial cells during pregnancy and have a 
comparable temporal and spatial relationship with VEGF (Mowa et al., 2004a). Tight 
junctions are also found between endothelial cells. Claudin-5 is a transmembrane protein and 
is primarily present in TJs of endothelia and has recently been localized to an epithelial cell 
line derived from human colon (HT-29/B6).  Three types of transmembrane proteins located 
in epithelial and endothelial TJs have been identified (Amasheh et al., 2005).  Although 
functional studies of claudin-5 have just begun recently, it has been localized to the tight 
junctions of both endothelial and epithelial cells in the intestine (Amasheh et al., 2005).    
Therefore, it is possible that cluadin-5 may mediate VEGF induction of immune cell 
migration into the cervical lumen.    
The cervical epithelium serves multiple roles in the female, depending on the 
physiological conditions.  The cervical epithelia, along with mucus, play an important 
protective role during pregnancy and the birth process (Timmons et al., 2010).  These roles 
also include prevention of intra-uterine infection, and protection against mechanical assault 
during delivery.  Epithelia accomplish these roles by undergoing marked proliferation during 
pregnancy (Timmons et al., 2010).  Other non-physical or mechanical roles include innate 
and adaptive immunity (Timmons et al., 2010).  The cervical epithelium has recently been 
shown to secrete cytokines and chemokines that recruit and activate inflammatory cells and 
antimicrobial factors that eliminate invading pathogens (Timmons et al., 2010).   
VEGF causes epithelial cell structural changes in the cervix.  The present study shows 
that VEGF treatment affects cervical epithelial cell structure and the amount of ciliated cells 
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present in the epithelium.  Based on observations, cervical epithelial cells in VEGF-treated 
animals appeared swollen with less defined boundaries in comparison to the control group; in 
addition, ciliated cells were also less abundant.   This suggests that VEGF may not only 
influence the growth of cervical epithelial cells, but also their overall viability, structure, as 
well as the presence of ciliated cells.  In addition, VEGF likely plays an important role in CR, 
in part, by influencing growth of cervical epithelial cells, a cell type believed to play a central 
role in CR, according to recent studies.  
 It is important to note that in the data presented in this paper, there were some 
significant differences between the endo-cervix and the ecto-cervix.  This could be due to the 
fact that the endo-cervix is comprised of simple columnar epithelial cells (Timmons et al., 
2010).  For instance, in some tissue types, including the cervix, simple columnar epithelium 
secrete mucus, which may act as a lubricant (Timmons & Mahendroo, 2007).  In contrast, 
ecto-cervical epithelium consists of stratified squamous, non-keratinized cells.  This type of 
epithelium is typically multilayered and found in tissues that with-stand mechanical or 
chemical insult, such as our skin and the vagina (Timmons et al., 2010).    
The functional significance of VEGF’s effects on cervical epithelia growth, as 
demonstrated here, is for now unclear. During CR, the cervix undergoes pronounced growth 
over the course of pregnancy (Burger & Sherwood, 1998). In a previous study it was found 
that in control rats, nearly 75% of the epithelial cells and 55% of the stromal cells in the 
cervix at term had proliferated during the second half of pregnancy (Burger & Sherwood, 
1998).  This dramatic increase in cervical epithelial growth may reflect its overall role in CR. 
Indeed, recent reports have suggested that cervical epithelial may play the central role during 
CR (Timmons et al., 2010). Since the epithelia accounts for a good portion of cervical 
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growth, it may be the major contributing tissue that provides the biomechanical resistance to 
the ever-increasing gravitational force exerted by the growing fetus on the cervix.  Our 
current results are consistent with previous studies using fetal lung, showing VEGF-induced 
increase in epithelia growth (Brown, England, Goss, Snyder & Acarregui, 2001). 
To date, cervical growth during pregnancy has been largely attributed to relaxin, a 
protein hormone produced by the ovarian corpus luteum and the breast during pregnancy 
(Burger & Sherwood, 1995). Like VEGF, relaxin also enhances angiogenesis and is known 
to induce vasodilation in some tissues, such as the kidneys (Mookerjee et al., 2006).  Relaxin 
also increases proliferation of epithelial and stromal cells in the rat cervix during the second 
half of pregnancy (Burger & Sherwood, 1995), and is known to stimulate expression of 
VEGF in cultured human endometrial cells (Burger & Sherwood, 1995). Taken together, we 
suggest that VEGF and relaxin in the cervix could either have a synergistic relationship or 
that VEGF maybe downstream of relaxin or vice versa.  Future studies should decipher the 
effects of VEGF on cervical epithelium growth from those of relaxin.           
 This study has shown that mRNA levels of VEGF and its receptors, KDR, and Flt-1, 
are lower earlier in pregnancy (day 11), but peak sharply in late pregnancy (day 17).  This 
trend of mRNA expression of VEGF and its receptors resembles those reported in our 
previous studies which used pregnant rats using Western blot, ELISA and confocal 
immunofluorescence (Mowa et al., 2004a).  In our earlier pregnant rat study, protein 
expression of VEGF and its receptors were overall lower in early pregnancy (day 8) compare 
to late pregnancy (day 22) (Mowa et al., 2004a).  
The treatment data of pregnant mice when treated with VEGF protein agents shows 
up-regulation of mRNA levels of VEGF and its receptors.  When treated with VEGF blocker 
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protein there was a down-regulation of mRNA levels of VEGF and its receptors, which 
implies that rising levels of VEGF over the course of pregnancy may stimulate a further 
increase in VEGF. It is interesting that the effects of exogenous VEGF on the expression of 
endogenous VEGF mRNA in ovariectomized non-pregnant mice are just the opposite, i.e., 
instead of inducing VEGF expression, it down-regulates it. It is not clear at this point why 
there seem to be an apparent discrepancy between these data. It is possible that presence of 
sex steroid hormones in pregnant mice may account for this difference.   
In conclusion, the present study has shown that VEGF induces multiple alterations in 
the cervical tissues of mice, notably increased epithelia growth, folding, edema, down 
regulation of tight junction molecules, such as claudin 5, which possibly results in increase in 
epithelial cell paracellular spaces leading to migration of WBC into cervical lumen. 
Collectively, these findings suggest that VEGF plays a role in CR by inducing physiological 
inflammation (WBC infiltration, tight junction molecules and paracellular spaces, and 
edema) and cervical growth (epithelial growth) during CR. 
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Figure 1.  Effect of VEGF on the ultra-structure of the ecto-cervical epithelial cells 
in non-pregnant ovariectomized mice as revealed by scanning electron 
microscopy: mice treated with VEGF recombinant protein 164 (B, D, F) (200ng/mouse, 
single treatment of either IP or intra-vaginal) induces folds (blue arrows) and a general 
swelling in cervical epithelial sheets compared to the control group (A, C, E), where cell 
types, ciliated (red stars) and non-ciliated (white stars), borders (short white arrows), are 
more distinct than in VEGF-treated mice (*). Red circle in A and B are sites on the ecto- 
side of the cervix from which images C-F were taken (n=1).  Magnification: A,B=x100; 
C,D = x 5,000; E,F=x10,000. 
* 
Control 200ng VEGF 
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Figure 2.  Effect of VEGF on the ultra-structure of the endo-cervical epithelial 
cells in non-pregnant ovariectomized mice as revealed by scanning electron 
microscopy:  mice treated with VEGF recombinant protein 164 (B, D, F) 
(200ng/mouse, single treatment of either IP or intra-vaginal) causes WBC (blue arrows) 
migration from cervical tissue into the cervical lumen and a change in cellular shape 
compared to the control group (A, C, E). Cells in control group (red stars) have distinct 
borders (red arrows) compared to those in VEGF-treated mice (*). Red circle in A and B 
are sites on the endo- side of the cervix from which images C-F were taken (n=3). 
Magnification: A, B=x100; C, D = x 5,000; E, F=x10,000. 
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Figure 3. Effect of VEGF on the expression of claudin-5 protein in cervical 
epithelial cells of non-pregnant, ovariectomized mice as revealed by 
immunofluorescence:  VEGF recombinant protein 164 (200ng/mouse, single 
treatment of either IP or intra-vaginal) diminished expression of claudin-5 protein (B) 
in a time-dependent fashion between intercellular gaps of cervical epithelial cells (e) in 
ovariectomized mice, shown here using confocal immunostaining. The maximum 
effects of VEGF occurred at about 4hrs (B). Claudin-5 expression in control group (A) 
were more pronounced and localized between the inter-epithelial space, the normal 
locale of claudin-5 (n=3). 
A B 
e 
e 
e 
e 
Control VEGF (4hrs) 
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4hr 45min 
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Figure 4. Effect of VEGF on cervical epithelial cell proliferation in non-pregnant 
ovariectomized mice as revealed by immunohistochemistry: VEGF recombinant protein 164 
(200ng/mouse, single treatment of either IP or intra-vaginal) induces proliferation of cervical 
epithelial cells in ovariectomized mice, shown here using bromodeoxyuridine (BrdU) 
immunostaining, a marker for proliferation (brown staining). The maximum proliferative effects of 
VEGF was observed at about 5hrs (C, F) and by the 6
th
 hr post VEGF treatment, BrdU 
immunostaining significantly diminished. Small intestines, which have a robust proliferation, were 
used as positive control tissue (G)(n=3).  
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of non-pregnant ovariectomized mice as 
revealed by qPCR: VEGF recombinant 
protein 164 (200ng/mouse, single treatment 
intra-vaginal) down-regulates the expression of 
Flt-1 (A), KDR (B), and VEGF (C) in the non-
pregnant ovariectomized mouse cervix.  This 
data is not statistically significant (n=3).  
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Figure 6. Expression profile of VEGF, 
Flt-1, and KDR mRNAs throughout 
pregnancy as revealed by qPCR: 
Throughout pregnancy the expression of Flt-
1 (A), KDR (B), and VEGF (C) in the 
pregnant mouse cervix gradually increases 
until day 17.  By day 17 VEGF, Flt-1 and 
KDR increase dramatically.  This data is not 
statistically significant (n=3).  
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Figure 7 Effect of VEGF and VEGF 
blocker on expression of VEGF, Flt-1, 
and KDR mRNAs in the cervix of 
pregnant mice during early (day 11) 
and late (day 17) of pregnancy as 
revealed by qPCR: VEGF recombinant 
protein 164 (200ng/mouse, single 
treatment intra-vaginal) up-regulates the 
expression of Flt-1 (A), KDR (B), and 
VEGF (C) in the pregnant mouse cervix at 
days 11 and 17 of pregnancy compared to 
control.  VEGF Blocker down-regulates 
the expression of Flt-1 (A), KDR (B), and 
VEGF (C) in the pregnant mouse cervix at 
days 11 and 17 of pregnancy compared to 
control.  This data is not statistically 
significant (n=3). (Horizontal Lines = 
VEGF Treated; Diagonal Crosses = VB 
Treated 
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Biographical Sketch 
 
 Siobhan Maureen Donnelly was born in Helena, Montana to parents Peter and Lynn 
on July 4, 1986.  She became a younger sister to Sarah, who is 13 months older and was born 
with Downs Syndrome.  Three years later, Sarah and Siobhan were blessed with the addition 
of their brother, Thomas, and five years after Tom, Mackenzie was born.  The four of the 
Donnelly children grew up in the beautiful mountains of Montana and were introduced to a 
variety of sports at a very young age.  Siobhan and her siblings became US and world 
travelers due to the fact that their father was originally from Australia.  They would make 
frequent trips down under to visit family and friends. 
 A 2004 Helena High graduate, Siobhan was a two-sport athlete in basketball and 
volleyball.  Following high school, she traveled to eastern Montana to attend Miles 
Community College on a basketball scholarship.  After one year at MCC, Siobhan 
transferred to a 4-year university to pursue her Bachelor’s degree.  University of Great Falls 
became the new campus and basketball team to Siobhan over the next 4 years.  She 
graduated from UGF in May 2010 with a Bachelors of Arts degree in pre-professional 
Biology with a minor in chemistry. 
 Upon college graduation, she decided to complete a Master of Science degree at 
Appalachian State University.  She has been studying female reproduction, specifically 
cervical remodeling, under the guidance of Dr. Nathan Mowa for the last two years.  After 
graduation, Siobhan will pursue a career in the cell and molecular field of research.     
